InvestorAda Ventures is a venture capital firm based in London and Bristol, UK, focusing on early-stage technology companies led by diverse founders. They invest in sectors such as climate equity, economic empowerment, and healthy aging.

Capital Cell is Europe's first dedicated equity crowdfunding platform for biotechnology and life sciences, based in Barcelona. It connects private investors with early-stage biotech startups, emphasizing expert vetting of investment opportunities.
Online destinations
Where to find this organization online, grouped by who runs each page. A link here does not mean the organization controls it.
Pages the organization runs itself.
Founded in 2015 by CEO Daniel Oliver, Capital Cell is an equity crowdfunding platform that specializes in biotechnology and life sciences. Based in Barcelona, Spain, it aims to democratize access to high-impact investments in the life sciences sector. The platform connects private investors with early-stage biotech and healthtech startups, utilizing a proprietary 'BioExpert Network' of over 800 opinion leaders and biomedical experts to vet projects before they are listed for investment. This unique approach differentiates Capital Cell from traditional crowdfunding platforms, allowing individuals to contribute to advancements in human health while providing startups with both capital and expert validation.
Capital Cell focuses on investing in biotechnology and life sciences companies through equity crowdfunding. The platform enables investors to participate in funding rounds for startups in these sectors, emphasizing a rigorous vetting process through its BioExpert Network of over 800 opinion leaders and biomedical experts.
Capital Cell adds value to its portfolio companies by providing access to a network of biomedical experts who offer scientific due diligence, enhancing the credibility of the startups. Additionally, the platform democratizes investment opportunities, allowing startups to raise capital from a diverse pool of investors.
Capital Cell invests in early-stage biotechnology and life sciences companies, focusing on pre-seed, seed, and seed+ rounds. The firm emphasizes a rigorous vetting process through its BioExpert Network, which consists of over 800 biomedical experts who evaluate each investment opportunity.
Startups interested in raising capital through Capital Cell can apply via their website. The platform has a selective acceptance rate of approximately 3%, ensuring that only the most promising companies are considered for funding.
Capital Cell operates as an equity crowdfunding platform specifically for biotech and life sciences, allowing individual investors to participate in funding rounds. This model democratizes access to investments that were previously limited to institutional investors, while also providing startups with validation from a network of biomedical experts.
Capital Cell primarily invests in European biotech startups, with a strong focus on Spain and an expanding presence in the UK and other European markets. The firm aims to support innovative health solutions across the continent.
While individual campaign check sizes are not specified, Capital Cell allows minimum investments starting at €100, making it accessible to a wide range of investors. The total amount raised varies by company and funding round.
Capital Cell provides access to its BioExpert Network for portfolio companies, offering scientific due diligence and support. This enhances the credibility of the startups and helps them navigate the challenges of growth and development in the biotech sector.
Superscout Pro
Is this page right?Reviewed · How the research works